New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Mahadeo, K. M., Baiocchi, R. A., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Nikiforow, S., Reshef, R., Ye, W., & Prockop, S. (2022). New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 140(Supplement 1), 10374–10376. https://doi.org/10.1182/blood-2022-157766
Authors:
Kris M. Mahadeo
Robert A. Baiocchi
Amer Beitinjaneh
Sridhar Chaganti
Sylvain Choquet
Daan Dierickx
Rajani Dinavahi
Laurence Gamelin
Armin Ghobadi
Norma Guzmán‐Becerra
Manher Joshi
Simar Rajan Singh
Sarah Nikiforow
Ran Reshef
Wei Ye
Susan E. Prockop
Affiliated Authors:
Ran Reshef
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
Lymphoid Neoplasms (OpenAlex Topic)
Viral-Related Cancers in Immunocompromised Patients (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2022-157766
DOI:
10.1182/blood-2022-157766
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: